Allogene Therapeutics, Inc. 10-K

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. Our common stock has been listed on The Nasdaq Global Select Market under the symbol “ALLO” since October 11, 2018. Prior to that date, there was no public trading market for our common stock. Holders of Common Stock As of February 23, 2022, there were approximately 62 holders of record of our common stock. Stock Performance Graph This performance graph shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or incorporated by reference into any of our filings under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. The following graph shows the value of an investment of $100 from October 11, 2018 (the date our common stock commenced trading on The Nasdaq Global Select Market) through December 31, 2021, in our common stock, the Standard & Poor’s 500 Index (S&P 500), the Nasdaq Biotechnology Index, and Nasdaq Composite Index. The historical stock price performance of our common stock shown in the performance graph is not necessarily indicative of future stock price performance. Cumulative Total Return date ended 10/11/2018 12/31/2018 6/30/2019 12/31/2019 6/30/2020 12/31/2020 6/30/2021 12/31/2021 Allogene Therapeutics, Inc. $ 100.00 $ 122.41 $ 122.05 $ 118.09 $ 194.64 $ 114.73 $ 118.55 $ 67.82 S&P 500 $ 100.00 $ 90.28 $ 105.94 $ 116.35 $ 111.65 $ 135.26 $ 154.76 $ 171.64 Nasdaq Biotechnology $ 100.00 $ 87.25 $ 98.26 $ 108.54 $ 123.19 $ 136.42 $ 147.57 $ 135.56 Nasdaq Composite $ 100.00 $ 89.81 $ 108.37 $ 121.45 $ 136.15 $ 174.45 $ 196.32 $ 211.76 Dividend Policy We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. We do not intend to pay cash dividends on our common stock for the foreseeable future. Any future determination related to our dividend 77 Table of Contents policy will be made at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our board of directors may deem relevant. Purchases of Equity Securities by the Issuer and Affiliated Purchasers None. Item 6. [Reserved]